ClinicalTrials.gov
ClinicalTrials.gov Menu

Branched-chain Amino Acids Supplementation and Resistance Exercise-induced Muscle Damage and Inflammation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01305018
Recruitment Status : Suspended
First Posted : February 28, 2011
Last Update Posted : May 5, 2011
Sponsor:
Information provided by:
University of Sao Paulo

Brief Summary:
This study aims to evaluate the effects of branched-chain amino acids (BCAA) supplementation on resistance exercise-induced muscle damage and inflammation.

Condition or disease Intervention/treatment Phase
Muscle Damage Inflammation Dietary Supplement: BCAA Dietary Supplement: Leucine Dietary Supplement: Placebo Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Effects of Leucine and Branched-chain Amino Acids (BCAA) Supplementation on Resistance Exercise-induced Muscle Damage and Inflammation: a Randomized, Double-blind, and Placebo-controlled Study
Study Start Date : August 2011
Estimated Primary Completion Date : January 2012
Estimated Study Completion Date : August 2012

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Exercise and BCAA Dietary Supplement: BCAA
7 g of leucine + 3,5 g of isoleucine + 3,5 g of valine per day during 9 days
Experimental: Exercise and Leucine Dietary Supplement: Leucine
7 g of leucine + 7 g of alanine per day during 9 days
Placebo Comparator: Exercise and Placebo Dietary Supplement: Placebo
14 g of alanine per day during 9 days



Primary Outcome Measures :
  1. Muscle maximal strength [ Time Frame: 4 days ]
  2. Muscle edema [ Time Frame: 4 days ]
  3. Muscle soreness [ Time Frame: 4 days ]

Secondary Outcome Measures :
  1. Muscle inflammation [ Time Frame: 4 days ]
    Immunohistochemistry, protein expression.

  2. Muscle damage [ Time Frame: 4 days ]
    Serum creatine kinase



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 30 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Sedentary;
  • No muscle disorders;
  • Must be able to swallow tablets

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01305018


Locations
Brazil
University of São Paulo - School of Physical Education and Sports
São Paulo, Brazil, 05508-030
Sponsors and Collaborators
University of Sao Paulo

Responsible Party: Claudia Ribeiro da Luz, University of São Paulo
ClinicalTrials.gov Identifier: NCT01305018     History of Changes
Other Study ID Numbers: 071287
First Posted: February 28, 2011    Key Record Dates
Last Update Posted: May 5, 2011
Last Verified: April 2011

Keywords provided by University of Sao Paulo:
Branched-chain amino acids
Leucine
Muscle damage
Inflammation
supplementation
resistance exercise-induced

Additional relevant MeSH terms:
Inflammation
Pathologic Processes